{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:59:26Z","timestamp":1789012766589,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D\u2010Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed\/refractory multiple myeloma (RRMM) who had received \u22651 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient\u2010reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5\u00a0months with D\u2010Pd and 6.6\u00a0months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ\u2010C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D\u2010Pd but worsened with Pd. Reductions (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) in pain and fatigue were seen at several time points with D\u2010Pd versus Pd. Overall, these results suggest patients' health\u2010related quality of life remained stable when daratumumab was added to Pd, with several results favoring D\u2010Pd versus Pd. These findings complement the significant clinical improvements observed with D\u2010Pd and support its use in patients with RRMM.<\/jats:p>","DOI":"10.1002\/ajh.26480","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T14:35:19Z","timestamp":1643380519000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Health\u2010related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone \u00b1 subcutaneous daratumumab: Patient\u2010reported outcomes from the APOLLO trial"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences University of Torino  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7523-7510","authenticated-orcid":false,"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[{"name":"Department of Hematology Evangelismos Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Hematology Ankara University  Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":false,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology Theagenio Cancer Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Hematology Department University Hospital H\u00f4tel\u2010Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pompa","sequence":"additional","affiliation":[{"name":"Hematology Unit University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-3473","authenticated-orcid":false,"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Patras  Patras Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[{"name":"Clinic of Hematology University of Belgrade  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia Hospital Germans Trias I Pujol  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hematology Department University Hospital of Salamanca\/IBSAL\/Cancer Research Center\u2010IBMCC (USAL\u2010CSIC)  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Orfanidis","sequence":"additional","affiliation":[{"name":"Health Data Specialists S.A.  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kampfenkel","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Qiu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Amin","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Wayne Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center Cancer Institute  Rotterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222299"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15248"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1747066"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1991-4"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02392-6"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4531.4531"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"e_1_2_12_24_1","volume-title":"DARZALEX\u00ae (Daratumumab) Injection, for Intravenous Use [Prescribing Information]","author":"Janssen Biotech, Inc","year":"2019"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01206.x"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01665.x"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-70"},{"key":"e_1_2_12_33_1","volume-title":"EORTC QLQ\u2010C30 reference values","author":"Scott NW","year":"2008"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.05.007"},{"key":"e_1_2_12_36_1","first-page":"1850","article-title":"Health\u2010related quality of life in patients with relapsed\/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: ICARIA\u2010MM study","volume":"134","author":"Houghton K","year":"2019","journal-title":"Am Soc Hematol"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17321"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17435"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6205"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T08:37:28Z","timestamp":1692434248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/ajh.26480"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26480","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"2021-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}